BioSpace News Archive

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended September 30, 2021,

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today it will be presenting new scientific research at the American College of Rheumatology’s (ACR) virtual annual meeting, ACR Convergence 2021.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), today announced that it will host a conference call on Thursday, November 4, 2021 at 4:30 PM ET to discuss its financial results and provide a business update for the third quarter 2021.

Accuray Incorporated, announced preliminary financial results for the first quarter of fiscal 2022 ended September 30, 2021.

MedX Health Corp. is pleased to announce that seasoned pharmaceutical finance executive Lesley Bourget has been appointed as the Company’s Chief Financial Officer, effective November 8th, 2021.

Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, announced the appointment of Scott Myers to its Board of Directors.

Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted today to recommend the use of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older.

Johnson & Johnson (the Company) (NYSE: JNJ) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), has recommended its COVID-19 vaccine as a booster for all eligible individuals who receive an authorized COVID-19 vaccine.

IVERIC bio, Inc., announced the pricing of an upsized underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $16.75 per share, less underwriting discounts and commissions.